Can I Take Green Tea Extract (EGCG) with Egrifta (Tesamorelin)?
At a glance
- Drug / Egrifta SV 1.4 mg or Egrifta WR 1.28 mg, subcutaneous once daily [1][2]
- Label interaction list / CYP450-metabolized drugs and glucocorticoids; green tea extract is not named [1][2]
- Label contraindications / Pituitary axis disruption, active malignancy, hypersensitivity, pregnancy [1][2]
- Caffeine in brewed green tea / About 37 mg per 12 fl oz [3]
- Tesamorelin half-life / About 8 minutes after a 1.4 mg Egrifta SV dose [1]
- Label monitoring / The labels call for glucose checks before and during treatment and IGF-1 monitoring during treatment [1][2]
What the Egrifta labels list
The Egrifta SV drug interaction section has two entries. CYP450-metabolized drugs: tesamorelin raises growth hormone, and published data suggest GH may alter clearance of compounds handled by CYP450 liver enzymes, including corticosteroids, sex steroids, anticonvulsants and cyclosporine; the label advises monitoring for potential interactions [1]. Glucocorticoids: GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1, so people on replacement for hypoadrenalism may need higher maintenance or stress doses, and cortisone acetate and prednisone are affected more than others [1]. Egrifta WR carries the same two entries [2].
Green tea extract, EGCG and catechins are not among the drugs named in those sections [1][2]. They are also not among the contraindications, which cover disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1][2].
Does the caffeine in green tea matter?
The labels do not name caffeine, but they advise monitoring for potential interactions with CYP450-metabolized drugs [1][2]. Caffeine is metabolized mainly by CYP1A2 [4][5], and brewed green tea supplies about 37 mg per 12 fl oz [3]. Whether tesamorelin changes caffeine's effects is unknown.
Green tea catechins and visceral fat
In a per-protocol analysis of 240 Japanese adults with visceral fat-type obesity, a 12-week trial found greater reductions in waist circumference and visceral fat area with 583 mg of catechins daily than with 96 mg daily [6]. That trial did not test catechins alongside tesamorelin [6]. Tesamorelin's own 412-patient trial found visceral adipose tissue fell 15.2% versus a 5.0% rise on placebo at 26 weeks [7], and the label says tesamorelin is not indicated for weight loss because its effect on weight is neutral [1].
What the labels say to watch for on tesamorelin
Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3; the label advises monitoring IGF-1 and considering discontinuation if it stays elevated (for example above 3 SDS), particularly if the fat-loss response is not robust [1]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26 [1]. Hypersensitivity reactions occurred in 4% of trial patients, and the label advises patients to seek prompt medical attention and stop treatment if one is suspected [1].
Frequently asked questions
Can I take green tea extract with Egrifta (tesamorelin)?
Does the caffeine in green tea interact with tesamorelin?
What does the Egrifta label say to monitor?
Will green tea catechins add to tesamorelin for belly fat?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Spilling the Beans: How Much Caffeine is Too Much? | FDA.
- Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2008;60(6):789-97.
- Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers | FDA.
- Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring). 2007;15(6):1473-83.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.